Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199274 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marcin Minta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Karol Marcinkowski University of Medical Sciences in Poznan, ul. Polna 33, 60-535 Poznan, Poland. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Infant, Premature, Polymorphism, Single Nucleotide, Prostaglandins. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center of Poland, National Science Center.
Themen: Neonatologie
Abstract (Originalsprache)
Patent ductus arteriosus (PDA) constitutes a significant clinical condition, frequently associated with a spectrum of complications that may profoundly compromise the health status of neonates, particularly those born preterm. Multiple predisposing factors—including prematurity, low birth weight, and respiratory insufficiency—have been consistently documented in the scientific literature. In this study, we investigated the influence of genetic polymorphisms in genes associated with the arachidonic acid–prostaglandin metabolic pathway. Specifically, we analyzed polymorphisms in genes encoding phospholipase A2 (rs10798059, rs1549637, rs4375, rs1805017, rs1051931), cyclooxygenase-1 (rs1236913), prostaglandin synthase 2 (rs13283456), and the prostaglandin E2 receptor EP4 (rs4613763). The study cohort comprised 99 preterm neonates born between 24 and 32 weeks of gestation. Genetic analyses were performed to identify polymorphisms in the aforementioned genes. Statistical evaluation demonstrated that selected polymorphic were significantly associated with an increased risk of patent ductus arteriosus development. This study represents a preliminary step toward elucidating the contribution of genetic variability to the pathogenesis of patent ductus arteriosus. Improved understanding of these molecular mechanisms may facilitate the early identification of neonates at increased risk and support the implementation of targeted monitoring and preventive strategies in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neonatology, Karol Marcinkowski University of Medical Sciences in Poznan, ul. Polna 33, 60-535 Poznan, Poland.
ORCID-Profile: Grażyna Kurzawińska
Förderung
- National Science Center of Poland
- National Science Center
Zitieren
APA
Minta, M., Kurzawińska, G., Minta, Z. B., Seremak Mrozikiewicz, A., & Szpecht, D. (2025). Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199274
Vancouver
Minta M, Kurzawińska G, Minta ZB, Seremak Mrozikiewicz A, Szpecht D. Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199274
BibTeX
@article{Minta2025,
author = {Minta, Marcin and Kurzawińska, Grażyna and Minta, Zuzanna-Banach and Seremak Mrozikiewicz, Agnieszka and Szpecht, Dawid},
title = {Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199274}
}
EUVIMED